Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 31

1.

T-Cell Densities in Brain Metastases Are Associated with Patient Survival Times and Diffusion Tensor MRI Changes.

Zakaria R, Platt-Higgins A, Rathi N, Radon M, Das S, Das K, Bhojak M, Brodbelt A, Chavredakis E, Jenkinson MD, Rudland PS.

Cancer Res. 2018 Feb 1;78(3):610-616. doi: 10.1158/0008-5472.CAN-17-1720. Epub 2017 Dec 6.

PMID:
29212855
2.

Erythropoietin drives breast cancer progression by activation of its receptor EPOR.

Chan KK, Matchett KB, Coulter JA, Yuen HF, McCrudden CM, Zhang SD, Irwin GW, Davidson MA, Rülicke T, Schober S, Hengst L, Jaekel H, Platt-Higgins A, Rudland PS, Mills KI, Maxwell P, El-Tanani M, Lappin TR.

Oncotarget. 2017 Jun 13;8(24):38251-38263. doi: 10.18632/oncotarget.16368.

3.

S100A4 Elevation Empowers Expression of Metastasis Effector Molecules in Human Breast Cancer.

Ismail TM, Bennett D, Platt-Higgins AM, Al-Medhity M, Barraclough R, Rudland PS.

Cancer Res. 2017 Feb 1;77(3):780-789. doi: 10.1158/0008-5472.CAN-16-1802. Epub 2016 Nov 10.

4.

Ran GTPase promotes cancer progression via Met recepto-rmediated downstream signaling.

Yuen HF, Chan KK, Platt-Higgins A, Dakir el-H, Matchett KB, Haggag YA, Jithesh PV, Habib T, Faheem A, Dean FA, Morgan R, Rudland PS, El-Tanani M.

Oncotarget. 2016 Nov 15;7(46):75854-75864. doi: 10.18632/oncotarget.12420.

5.

Metastasis-inducing proteins are widely expressed in human brain metastases and associated with intracranial progression and radiation response.

Zakaria R, Platt-Higgins A, Rathi N, Crooks D, Brodbelt A, Chavredakis E, Lawson D, Jenkinson MD, Rudland PS.

Br J Cancer. 2016 May 10;114(10):1101-8. doi: 10.1038/bjc.2016.103. Epub 2016 Apr 21.

6.

RanGTPase: a candidate for Myc-mediated cancer progression.

Yuen HF, Gunasekharan VK, Chan KK, Zhang SD, Platt-Higgins A, Gately K, O'Byrne K, Fennell DA, Johnston PG, Rudland PS, El-Tanani M.

J Natl Cancer Inst. 2013 Apr 3;105(7):475-88. doi: 10.1093/jnci/djt028. Epub 2013 Mar 6.

PMID:
23468463
7.

Aberrant expression of metastasis-inducing proteins in ectopic and matched eutopic endometrium of women with endometriosis: implications for the pathogenesis of endometriosis.

Hapangama DK, Raju RS, Valentijn AJ, Barraclough D, Hart A, Turner MA, Platt-Higgins A, Barraclough R, Rudland PS.

Hum Reprod. 2012 Feb;27(2):394-407. doi: 10.1093/humrep/der412. Epub 2011 Dec 6.

PMID:
22147918
8.

Ran is a potential therapeutic target for cancer cells with molecular changes associated with activation of the PI3K/Akt/mTORC1 and Ras/MEK/ERK pathways.

Yuen HF, Chan KK, Grills C, Murray JT, Platt-Higgins A, Eldin OS, O'Byrne K, Janne P, Fennell DA, Johnston PG, Rudland PS, El-Tanani M.

Clin Cancer Res. 2012 Jan 15;18(2):380-91. doi: 10.1158/1078-0432.CCR-11-2035. Epub 2011 Nov 16.

9.

Statistical association of basal cell keratins with metastasis-inducing proteins in a prognostically unfavorable group of sporadic breast cancers.

de Silva Rudland S, Platt-Higgins A, Winstanley JH, Jones NJ, Barraclough R, West C, Carroll J, Rudland PS.

Am J Pathol. 2011 Aug;179(2):1061-72. doi: 10.1016/j.ajpath.2011.04.022. Epub 2011 Jun 14.

10.

Osteopontin can act as an effector for a germline mutation of BRCA1 in malignant transformation of breast cancer-related cells.

El-Tanani MK, Yuen HF, Shi Z, Platt-Higgins A, Buckley NE, Mullan PB, Harkin DP, Johnston PG, Rudland PS.

Cancer Sci. 2010 Jun;101(6):1354-60. doi: 10.1111/j.1349-7006.2010.01561.x. Epub 2010 Mar 10.

11.

Significance of the Fanconi anemia FANCD2 protein in sporadic and metastatic human breast cancer.

Rudland PS, Platt-Higgins AM, Davies LM, de Silva Rudland S, Wilson JB, Aladwani A, Winstanley JH, Barraclough DL, Barraclough R, West CR, Jones NJ.

Am J Pathol. 2010 Jun;176(6):2935-47. doi: 10.2353/ajpath.2010.090779. Epub 2010 Apr 2.

12.

The metastasis-associated anterior gradient 2 protein is correlated with poor survival of breast cancer patients.

Barraclough DL, Platt-Higgins A, de Silva Rudland S, Barraclough R, Winstanley J, West CR, Rudland PS.

Am J Pathol. 2009 Nov;175(5):1848-57. doi: 10.2353/ajpath.2009.090246. Epub 2009 Oct 15.

13.

Significance of the metastasis-inducing protein AGR2 for outcome in hormonally treated breast cancer patients.

Innes HE, Liu D, Barraclough R, Davies MP, O'Neill PA, Platt-Higgins A, de Silva Rudland S, Sibson DR, Rudland PS.

Br J Cancer. 2006 Apr 10;94(7):1057-65.

14.

Association of S100A4 and osteopontin with specific prognostic factors and survival of patients with minimally invasive breast cancer.

de Silva Rudland S, Martin L, Roshanlall C, Winstanley J, Leinster S, Platt-Higgins A, Carroll J, West C, Barraclough R, Rudland P.

Clin Cancer Res. 2006 Feb 15;12(4):1192-200.

15.

Induction of metastasis by S100P in a rat mammary model and its association with poor survival of breast cancer patients.

Wang G, Platt-Higgins A, Carroll J, de Silva Rudland S, Winstanley J, Barraclough R, Rudland PS.

Cancer Res. 2006 Jan 15;66(2):1199-207.

16.

Human homologue of cement gland protein, a novel metastasis inducer associated with breast carcinomas.

Liu D, Rudland PS, Sibson DR, Platt-Higgins A, Barraclough R.

Cancer Res. 2005 May 1;65(9):3796-805.

17.

Ets gene PEA3 cooperates with beta-catenin-Lef-1 and c-Jun in regulation of osteopontin transcription.

El-Tanani M, Platt-Higgins A, Rudland PS, Campbell FC.

J Biol Chem. 2004 May 14;279(20):20794-806. Epub 2004 Feb 27.

18.

Prognostic significance of the metastasis-associated protein osteopontin in human breast cancer.

Rudland PS, Platt-Higgins A, El-Tanani M, De Silva Rudland S, Barraclough R, Winstanley JH, Howitt R, West CR.

Cancer Res. 2002 Jun 15;62(12):3417-27.

19.

Comparison of the metastasis-inducing protein S100A4 (p9ka) with other prognostic markers in human breast cancer.

Platt-Higgins AM, Renshaw CA, West CR, Winstanley JH, De Silva Rudland S, Barraclough R, Rudland PS.

Int J Cancer. 2000 Mar 20;89(2):198-208.

20.

Expression of calcium-binding protein S100A2 in breast lesions.

Liu D, Rudland PS, Sibson DR, Platt-Higgins A, Barraclough R.

Br J Cancer. 2000 Dec;83(11):1473-9.

21.

Variant estrogen receptor alpha mRNAs in human breast cancer specimens.

Anandappa SY, Sibson R, Platt-Higgins A, Winstanley JH, Rudland PS, Barraclough R.

Int J Cancer. 2000 Oct 15;88(2):209-16.

22.

Prognostic significance of the metastasis-inducing protein S100A4 (p9Ka) in human breast cancer.

Rudland PS, Platt-Higgins A, Renshaw C, West CR, Winstanley JH, Robertson L, Barraclough R.

Cancer Res. 2000 Mar 15;60(6):1595-603.

23.

Development of hyperplasias, preneoplasias, and mammary tumors in MMTV-c-erbB-2 and MMTV-TGFalpha transgenic rats.

Davies BR, Platt-Higgins AM, Schmidt G, Rudland PS.

Am J Pathol. 1999 Jul;155(1):303-14.

24.

Human S100A4 (p9Ka) induces the metastatic phenotype upon benign tumour cells.

Lloyd BH, Platt-Higgins A, Rudland PS, Barraclough R.

Oncogene. 1998 Jul 30;17(4):465-73.

25.

Cytoplasmic staining of c-erbB-2 is not associated with the presence of detectable c-erbB-2 mRNA in breast cancer specimens.

Taylor SL, Platt-Higgins A, Rudland PS, Winstanley JH, Barraclough R.

Int J Cancer. 1998 May 18;76(4):459-63.

26.

Immunocytochemical distribution of the calcium-binding protein p9Ka in normal rat tissues: variation in the cellular location in different tissues.

Gibbs FE, Barraclough R, Platt-Higgins A, Rudland PS, Wilkinson MC, Parry EW.

J Histochem Cytochem. 1995 Feb;43(2):169-80.

PMID:
7822773
27.
28.
29.

Prognostic significance of cathepsin-D in patients with breast cancer.

Winstanley JH, Leinster SJ, Cooke TG, Westley BR, Platt-Higgins AM, Rudland PS.

Br J Cancer. 1993 Apr;67(4):767-72.

30.

The long term prognostic significance of c-erbB-2 in primary breast cancer.

Winstanley J, Cooke T, Murray GD, Platt-Higgins A, George WD, Holt S, Myskov M, Spedding A, Barraclough BR, Rudland PS.

Br J Cancer. 1991 Mar;63(3):447-50.

31.

Morphogenetic behavior of simian virus 40-transformed human mammary epithelial stem cell lines on collagen gels.

Rudland PS, Ollerhead GE, Platt-Higgins AM.

In Vitro Cell Dev Biol. 1991 Feb;27A(2):103-12.

PMID:
1708370

Supplemental Content

Loading ...
Support Center